HRP20220609T1 - Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija - Google Patents
Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija Download PDFInfo
- Publication number
- HRP20220609T1 HRP20220609T1 HRP20220609TT HRP20220609T HRP20220609T1 HR P20220609 T1 HRP20220609 T1 HR P20220609T1 HR P20220609T T HRP20220609T T HR P20220609TT HR P20220609 T HRP20220609 T HR P20220609T HR P20220609 T1 HRP20220609 T1 HR P20220609T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- compound
- use according
- phenyl
- formula
- Prior art date
Links
- 238000006243 chemical reaction Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- -1 3-chloro-4-fluorophenyl Chemical group 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 6
- 239000012828 PI3K inhibitor Substances 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 229940121647 egfr inhibitor Drugs 0.000 claims 3
- 229960003445 idelalisib Drugs 0.000 claims 3
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 3
- 239000000243 solution Substances 0.000 claims 3
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 claims 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 2
- 208000010201 Exanthema Diseases 0.000 claims 2
- 229940124647 MEK inhibitor Drugs 0.000 claims 2
- 229950003628 buparlisib Drugs 0.000 claims 2
- 229960002271 cobimetinib Drugs 0.000 claims 2
- 239000006071 cream Substances 0.000 claims 2
- 229950006418 dactolisib Drugs 0.000 claims 2
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007933 dermal patch Substances 0.000 claims 2
- 201000005884 exanthem Diseases 0.000 claims 2
- 239000006260 foam Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 230000003779 hair growth Effects 0.000 claims 2
- 239000000017 hydrogel Substances 0.000 claims 2
- 239000006210 lotion Substances 0.000 claims 2
- 206010037844 rash Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000007921 spray Substances 0.000 claims 2
- 238000007910 systemic administration Methods 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- YOVVNQKCSKSHKT-HNNXBMFYSA-N (2s)-1-[4-[[2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one Chemical group C1CN(C(=O)[C@@H](O)C)CCN1CC1=C(C)C2=NC(C=3C=NC(N)=NC=3)=NC(N3CCOCC3)=C2S1 YOVVNQKCSKSHKT-HNNXBMFYSA-N 0.000 claims 1
- GFMMXOIFOQCCGU-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide Chemical compound C=1C=C(I)C=C(Cl)C=1NC1=C(F)C(F)=CC=C1C(=O)NOCC1CC1 GFMMXOIFOQCCGU-UHFFFAOYSA-N 0.000 claims 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 claims 1
- RCLQNICOARASSR-SECBINFHSA-N 3-[(2r)-2,3-dihydroxypropyl]-6-fluoro-5-(2-fluoro-4-iodoanilino)-8-methylpyrido[2,3-d]pyrimidine-4,7-dione Chemical compound FC=1C(=O)N(C)C=2N=CN(C[C@@H](O)CO)C(=O)C=2C=1NC1=CC=C(I)C=C1F RCLQNICOARASSR-SECBINFHSA-N 0.000 claims 1
- 206010067484 Adverse reaction Diseases 0.000 claims 1
- 206010019044 Hair growth abnormal Diseases 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
- SUDAHWBOROXANE-SECBINFHSA-N PD 0325901 Chemical compound OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F SUDAHWBOROXANE-SECBINFHSA-N 0.000 claims 1
- 206010034016 Paronychia Diseases 0.000 claims 1
- 241000029132 Paronychia Species 0.000 claims 1
- 206010037649 Pyogenic granuloma Diseases 0.000 claims 1
- 206010037888 Rash pustular Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010040914 Skin reaction Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 230000006838 adverse reaction Effects 0.000 claims 1
- ACWZRVQXLIRSDF-UHFFFAOYSA-N binimetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1F ACWZRVQXLIRSDF-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 claims 1
- RESIMIUSNACMNW-BXRWSSRYSA-N cobimetinib fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F.C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F RESIMIUSNACMNW-BXRWSSRYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950004949 duvelisib Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 210000000720 eyelash Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 230000000116 mitigating effect Effects 0.000 claims 1
- 229960000513 necitumumab Drugs 0.000 claims 1
- 229960003278 osimertinib Drugs 0.000 claims 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 claims 1
- 229960001972 panitumumab Drugs 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100000289 photo-effect Toxicity 0.000 claims 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 210000004761 scalp Anatomy 0.000 claims 1
- 229950010746 selumetinib Drugs 0.000 claims 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 230000035483 skin reaction Effects 0.000 claims 1
- 231100000430 skin reaction Toxicity 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical group CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 229960000241 vandetanib Drugs 0.000 claims 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 claims 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762538675P | 2017-07-29 | 2017-07-29 | |
| EP18841422.1A EP3661515B1 (en) | 2017-07-29 | 2018-07-26 | Novel braf inhibitors and use thereof for treatment of cutaneous reactions |
| PCT/IL2018/050836 WO2019026065A2 (en) | 2017-07-29 | 2018-07-26 | NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220609T1 true HRP20220609T1 (hr) | 2022-06-24 |
Family
ID=65233550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220609TT HRP20220609T1 (hr) | 2017-07-29 | 2018-07-26 | Novi braf inhibitori i njihovo korištenje za tretiranje kožnih reakcija |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10927112B2 (enExample) |
| EP (1) | EP3661515B1 (enExample) |
| JP (1) | JP6912667B2 (enExample) |
| KR (1) | KR102328351B1 (enExample) |
| CN (1) | CN111132680B (enExample) |
| AU (1) | AU2018311538B2 (enExample) |
| CA (1) | CA3070542C (enExample) |
| DK (1) | DK3661515T3 (enExample) |
| ES (1) | ES2908602T3 (enExample) |
| HR (1) | HRP20220609T1 (enExample) |
| IL (1) | IL272312B (enExample) |
| MX (1) | MX383386B (enExample) |
| SI (1) | SI3661515T1 (enExample) |
| WO (1) | WO2019026065A2 (enExample) |
| ZA (1) | ZA202000354B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11458139B2 (en) * | 2017-08-08 | 2022-10-04 | Memorial Sloan Kettering Cancer Center | Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor |
| MX2021009535A (es) | 2019-02-12 | 2022-10-10 | Lutris Pharma Ltd | Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación. |
| WO2022136912A1 (en) * | 2020-12-24 | 2022-06-30 | Lutris Pharma Ltd. | Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions |
| WO2023275620A2 (en) * | 2021-07-02 | 2023-01-05 | Lutris Pharma Ltd. | Use of isoquinoline-1,5-diamines for wound healing |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753612A (en) | 1992-10-27 | 1998-05-19 | Yissum Research Development Co. Of The Hebrew University Of Jerusalem | Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists |
| US7989461B2 (en) | 2005-12-23 | 2011-08-02 | Amgen Inc. | Substituted quinazolinamine compounds for the treatment of cancer |
| US8557830B2 (en) * | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| TWI611053B (zh) | 2012-02-27 | 2018-01-11 | 曾宇鳳 | 為先導藥物最適化之以結構為基礎的片段遷越及合成可行性之改良 |
| KR20140011780A (ko) | 2012-07-19 | 2014-01-29 | 한미약품 주식회사 | 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체 |
| RU2015149937A (ru) * | 2013-05-30 | 2017-07-06 | Плексксикон Инк. | Соединения для модулирования киназы и показания к их применению |
| CN106535900A (zh) * | 2014-05-06 | 2017-03-22 | 加利福尼亚大学董事会 | 使用braf抑制剂的伤口愈合 |
| CN109069511A (zh) | 2016-03-10 | 2018-12-21 | 鲁特里斯制药有限公司 | Braf抑制剂用于治疗皮肤反应的用途 |
-
2018
- 2018-07-26 SI SI201830670T patent/SI3661515T1/sl unknown
- 2018-07-26 KR KR1020207005707A patent/KR102328351B1/ko active Active
- 2018-07-26 JP JP2020526718A patent/JP6912667B2/ja active Active
- 2018-07-26 EP EP18841422.1A patent/EP3661515B1/en active Active
- 2018-07-26 CN CN201880060593.7A patent/CN111132680B/zh active Active
- 2018-07-26 WO PCT/IL2018/050836 patent/WO2019026065A2/en not_active Ceased
- 2018-07-26 AU AU2018311538A patent/AU2018311538B2/en active Active
- 2018-07-26 MX MX2020000939A patent/MX383386B/es unknown
- 2018-07-26 DK DK18841422.1T patent/DK3661515T3/da active
- 2018-07-26 CA CA3070542A patent/CA3070542C/en active Active
- 2018-07-26 ES ES18841422T patent/ES2908602T3/es active Active
- 2018-07-26 HR HRP20220609TT patent/HRP20220609T1/hr unknown
-
2019
- 2019-06-13 US US16/440,601 patent/US10927112B2/en active Active
-
2020
- 2020-01-17 ZA ZA2020/00354A patent/ZA202000354B/en unknown
- 2020-01-28 IL IL272312A patent/IL272312B/en active IP Right Grant
- 2020-11-20 US US17/100,181 patent/US11339163B2/en active Active
-
2022
- 2022-05-17 US US17/746,446 patent/US20220274988A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020528933A (ja) | 2020-10-01 |
| ES2908602T3 (es) | 2022-05-03 |
| JP6912667B2 (ja) | 2021-08-04 |
| BR112020001935A2 (pt) | 2020-07-28 |
| ZA202000354B (en) | 2024-01-31 |
| RU2020108782A3 (enExample) | 2021-09-02 |
| WO2019026065A2 (en) | 2019-02-07 |
| US20210070757A1 (en) | 2021-03-11 |
| EP3661515B1 (en) | 2022-02-23 |
| KR20200035990A (ko) | 2020-04-06 |
| CA3070542C (en) | 2021-05-18 |
| KR102328351B1 (ko) | 2021-11-19 |
| CA3070542A1 (en) | 2019-02-07 |
| MX383386B (es) | 2025-03-13 |
| CN111132680B (zh) | 2022-02-08 |
| EP3661515A2 (en) | 2020-06-10 |
| CN111132680A (zh) | 2020-05-08 |
| EP3661515A4 (en) | 2021-01-06 |
| AU2018311538B2 (en) | 2021-03-25 |
| DK3661515T3 (da) | 2022-04-19 |
| SI3661515T1 (sl) | 2022-06-30 |
| AU2018311538A1 (en) | 2020-02-13 |
| RU2020108782A (ru) | 2021-09-02 |
| US20190389862A1 (en) | 2019-12-26 |
| IL272312B (en) | 2021-06-30 |
| US11339163B2 (en) | 2022-05-24 |
| US10927112B2 (en) | 2021-02-23 |
| IL272312A (en) | 2020-03-31 |
| WO2019026065A3 (en) | 2019-08-01 |
| US20220274988A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7698749B2 (ja) | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 | |
| Galimont-Collen et al. | Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors | |
| ES2695931T3 (es) | Composiciones y métodos para estimular el crecimiento del pelo | |
| RU2018135483A (ru) | Использование ингибиторов braf для лечения кожных реакций | |
| CA2763299C (en) | Method for treating or ameliorating mucocutaneous or ocular toxicities | |
| RU2015122627A (ru) | Кожные композиции, содержащие неприродные гигроскопические аминокислоты | |
| US11684567B2 (en) | Compositions and methods for treating an infection | |
| US11173163B2 (en) | Topical antimicrobial compositions and methods of formulating the same | |
| US20180235984A1 (en) | Tetracycline management of egfr inhibitor associated dermatoses | |
| JP2021530463A (ja) | ｍＴＯＲ阻害剤の無水組成物および使用方法 | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| US20190167527A1 (en) | Topical antimicrobial compositions and methods of formulating the same | |
| US12029812B2 (en) | Compositions and methods for treating an infection | |
| JP2020528933A5 (enExample) | ||
| HRP20221230T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu | |
| US20160279245A1 (en) | Topical formulations, systems, and methods | |
| JP6659819B2 (ja) | 化学療法に関連する脱毛の軽減方法 | |
| Kerure et al. | Real-world effectiveness, safety, and tolerability of cetosomal minoxidil 5% alone and a fixed drug combination of cetosomal minoxidil 5% with finasteride 0.1% in the management of androgenetic alopecia (Inbilt Study) | |
| US9402823B2 (en) | Ingenols for treating seborrheic keratosis | |
| US8163764B2 (en) | Skincare methods | |
| RU2020108782A (ru) | Новые ингибиторы braf и их применение для лечения кожных реакций | |
| CN103442692A (zh) | 病毒性感染的治疗 | |
| RU2197235C1 (ru) | Раствор для лечения заболеваний кожи, способ его получения и способ лечения заболеваний кожи | |
| TWI519316B (zh) | 皮膚不適之治療 | |
| CN112494488B (zh) | 瑞巴派特的防脱发和生发用途 |